Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of...
Harbour BioMed ("HBM", HKEX:02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel...
Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), today announced the appointment of Dr. Humphrey Gardner as Chief Medical Officer (CMO). Dr....
Harbour BioMed ("HBM", "the Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization ...
Harbour BioMed ("HBM", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel...
Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and...
Harbour BioMed ("HBM", HKEX: 02142) announced that, it has been approved by the Institutional Review Boards (the "IRBs") to commence phase I trial of ...
Harbour BioMed ("HBM", HKEX: 02142) announced that China National Medical Products Administration (NMPA) had approved its investigational new drug...
Harbour BioMed ("HBM", HKEX: 02142) announced that, it has successfully completed the dosing of first patient in phase Ib/IIa trial at the stage of...
Harbour BioMed ("HBM", HKEX: 02142) announced that, its next generation anti-CTLA-4 fully human heavy-chain only antibody (HCAb), HBM4003, has...
Harbour BioMed ("HBM", HKEX:02142) is pleased to announce the appointment of Mr. Weihao Xu as Chief Strategy Officer (CSO), who will base in San...
Harbour BioMed ("HBM", HKEX: 02142) announced that, the clinical trial of its anti-FcRn antibody, batoclimab (HBM9161), has completed the first...
Harbour BioMed ("HBM", HKEX: 02142) announced that the China National Medical Products Administration (NMPA) has approved its Investigational New...
Harbour BioMed ("HBM", HKEX: 02142) announced positive results from its phase I dose escalation clinical trial of HBM4003 in solid tumors in...
Harbour BioMed ("HBM", HKEX: 02142) today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration...
Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and...
Harbour BioMed ("HBM", HKEX: 02142) today announced that the abstract detailing clinical data from its Australian phase I study of next-generation...
Harbour BioMed ("HBM", HKEX:02142) announced the appointment of Dr. Yingying Chen as Chief Financial Officer (CFO). Dr. Chen will be responsible for...
Harbour BioMed ("HBM", HKEX: 02142) today announced positive topline results from its Phase 2 proof-of-concept clinical trial of batoclimab (HBM9161) ...
Harbour BioMed ("HBM", HKEX: 02142) today announced the dosing of the first patient of HBM4003 in patients with advanced non-small cell lung cancer...
Harbour BioMed (HKEX: 02142) announced today it has entered into a multi-year, multifaceted research collaboration agreement with Dana-Farber Cancer...
Harbour BioMed ("HBM", HKEX: 02142) today announced the dosing of the first patient in its part 2 of phase I (phase Ib/IIa) clinical study of its...
Harbour BioMed ("HBM"; HKEX: 02142.HK), a global clinical-stage biopharmaceutical company, presents its newly discovered fully human anti-B7H7...
Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the first patient in its open Phase I clinical study of HBM4003 for Chinese patients ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.